Lawrence Blonde
YOU?
Author Swipe
View article: MON-572 Characterization of Individuals With Difficult-to-Control Type 2 Diabetes and Post-Dexamethasone Suppression Test Cortisol Values <1.2, 1.2-1.8, and >1.8 µg/dL: Findings From the CATALYST Part 1 Study
MON-572 Characterization of Individuals With Difficult-to-Control Type 2 Diabetes and Post-Dexamethasone Suppression Test Cortisol Values <1.2, 1.2-1.8, and >1.8 µg/dL: Findings From the CATALYST Part 1 Study Open
Disclosure: R.J. Auchus: Neurocrine Biosciences/Neurocrine UK, LTD, Spruce Biosciences, Corcept Therapeutics, Crinetics Pharmaceuticals, Recordati Rare Diseases, Adrenas Therapeutics, Mineralys Pharmaceuticals, Quest Diagnostics, Xeris Pha…
View article: Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment Open
OBJECTIVE In many individuals, type 2 diabetes (T2D) remains poorly controlled despite taking multiple glucose-lowering therapies. Several studies have demonstrated that endogenous hypercortisolism is prevalent among these individuals. We …
View article: Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes Open
OBJECTIVE Despite the use of multiple glucose-lowering medications, glycemic targets are not met in a significant fraction of people with type 2 diabetes. In this prospective, observational study we assessed the prevalence of hypercortisol…
View article: Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone Open
Introduction Even with recent treatment advances, type 2 diabetes (T2D) remains poorly controlled for many patients, despite the best efforts to adhere to therapies and lifestyle modifications. Although estimates vary, studies indicate tha…
View article: FRI183 Phase 4 Study Of Hypercortisolism In Patients With Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence And Treatment With Mifepristone
FRI183 Phase 4 Study Of Hypercortisolism In Patients With Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence And Treatment With Mifepristone Open
Disclosure: J.P. Frias: Advisory Board Member; Self; Corcept Therapeutics. Consulting Fee; Self; Corcept Therapeutics. Other; Self; Corcept Therapeutics. R.J. Auchus: Consulting Fee; Self; Corcept Therapeutics. Grant Recipient; Self; Corce…
View article: Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results
Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results Open
The above infographic represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The a…
View article: Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of <scp>LIRA‐ADD2SGLT2i</scp>
Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of <span>LIRA‐ADD2SGLT2i</span> Open
Aims The LIRA‐ADD2SGLT2i trial demonstrated that liraglutide + sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) ± metformin significantly improved glycaemic control (not body weight) versus placebo in adults with type 2 diabetes (T2D). …
View article: Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus Open
Introduction To assess secondary metformin monotherapy (MM) failure in a real-world type 2 diabetes mellitus (T2DM) cohort. Research design and methods Using the IQVIA Electronic Medical Record (formerly GE Centricity) database, adults wit…
View article: Improving Management of Type 2 Diabetes Using Home-Based Telemonitoring: Cohort Study
Improving Management of Type 2 Diabetes Using Home-Based Telemonitoring: Cohort Study Open
Background Diabetes is present in 10.5% of the US population and accounts for 14.3% of all office-based physician visits made by adults. Despite this established office-based approach, the disease and its adverse outcomes including glycemi…
View article: Insulin glargine 300 units/ <scp>mL</scp> for the treatment of individuals with type 2 diabetes in the real world: A review of the <scp>DELIVER</scp> programme
Insulin glargine 300 units/ <span>mL</span> for the treatment of individuals with type 2 diabetes in the real world: A review of the <span>DELIVER</span> programme Open
Evidence from randomized controlled trials (RCTs) has shown that second‐generation basal insulin (BI) analogues, insulin glargine 300 U/mL (Gla‐300) and insulin degludec (IDeg), provide similar glycaemic control, with a lower risk of hypog…
View article: Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes Open
Article full text The above infographic and summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-revi…
View article: Switching to <scp>iGlarLixi</scp> versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist ( <scp>GLP</scp> ‐1 <scp>RA</scp> ) in insufficiently controlled type 2 diabetes: A <scp>LixiLan‐G</scp> trial subgroup analysis by HbA1c and <scp>GLP</scp> ‐1 <scp>RA</scp> use at screening
Switching to <span>iGlarLixi</span> versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist ( <span>GLP</span> ‐1 <span>RA</span> ) in insufficiently controlled type 2 diabetes: A <span>LixiLan‐G</span> trial subgroup analysis by HbA1c and <span>GLP</span> ‐1 <span>RA</span> use at screening Open
Aim In people with type 2 diabetes (T2D) requiring intensification beyond glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and oral antihyperglycaemic drugs (OADs), switching to iGlarLixi was shown to be efficacious and well‐tolerated…
View article: Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study Open
Objective In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine 100 units/mL and the glucagon-like peptide-1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control i…
View article: Author response for "Switching to iGlarLixi vs Continuation of Daily or Weekly GLP ‐1 RA in Insufficiently Controlled Type 2 Diabetes: A LixiLan‐G Trial Subgroup Analysis by HbA 1c and GLP ‐1 RA Use at Screening"
Author response for "Switching to iGlarLixi vs Continuation of Daily or Weekly GLP ‐1 RA in Insufficiently Controlled Type 2 Diabetes: A LixiLan‐G Trial Subgroup Analysis by HbA 1c and GLP ‐1 RA Use at Screening" Open
Aim In people with type 2 diabetes (T2D) requiring intensification beyond glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and oral antihyperglycaemic drugs (OADs), switching to iGlarLixi was shown to be efficacious and well-tolerated…
View article: Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study Open
Objective In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine 100 units/mL and the glucagon-like peptide-1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control i…
View article: Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study Open
Objective In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine 100 units/mL and the glucagon-like peptide-1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control i…
View article: Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study Open
OBJECTIVE In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control i…
View article: A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes
A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes Open
Each January, the editors of Diabetes Care look back at the last year and forward to the next. In January 2021 we have much to be thankful and happy about. The journal continues to publish outstanding scientific reports together with illum…
View article: Improving Management of Type 2 Diabetes Using Home-Based Telemonitoring: Cohort Study (Preprint)
Improving Management of Type 2 Diabetes Using Home-Based Telemonitoring: Cohort Study (Preprint) Open
BACKGROUND Diabetes is present in 10.5% of the US population and accounts for 14.3% of all office-based physician visits made by adults. Despite this established office-based approach, the disease and its adverse outcomes including glycem…
View article: Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo
Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo Open
Oral semaglutide is a tablet formulation of a glucagon-like peptide-1 receptor agonist (GLP-1RA), recently approved in the USA and other countries. This paper reviews data from clinical trials (PIONEER 1, 2, 3, and 7) comparing oral semagl…
View article: Insulin glargine/lixisenatide fixed‐ratio combination ( <scp>iGlarLixi</scp> ) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis
Insulin glargine/lixisenatide fixed‐ratio combination ( <span>iGlarLixi</span> ) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis Open
Aim To assess the efficacy and safety of iGlarLixi, a fixed‐ratio combination of insulin glargine 100 U/mL and lixisenatide, relative to premix insulin and other insulin options through network meta‐analysis. Methods A systematic literatur…
View article: Efficacy and safety of <scp>iGlarLixi</scp> versus <scp>IDegLira</scp> in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison
Efficacy and safety of <span>iGlarLixi</span> versus <span>IDegLira</span> in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison Open
Aims To estimate the relative treatment effect between the fixed‐ratio combinations iGlarLixi and IDegLira (glucagon‐like peptide 1 receptor agonist with basal insulin) in people with type 2 diabetes inadequately controlled on a glucagon‐l…
View article: Insulin glargine 300 U/ <scp>mL</scp> versus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes of <scp>ACHIEVE</scp> Control, a prospective, randomized, pragmatic real‐life clinical trial
Insulin glargine 300 U/ <span>mL</span> versus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes of <span>ACHIEVE</span> Control, a prospective, randomized, pragmatic real‐life clinical trial Open
Aim To report the effectiveness and safety of insulin glargine 300 U/mL (Gla‐300) versus standard‐of‐care basal insulin analogues (SOC‐BI) at 12 months in the ACHIEVE Control trial, which is a prospective pragmatic randomized real‐life stu…
View article: Author response for "Insulin glargine/lixisenatide fixed‐ratio combination ( <scp>iGlarLixi</scp> ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis"
Author response for "Insulin glargine/lixisenatide fixed‐ratio combination ( <span>iGlarLixi</span> ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis" Open
Aim To assess the efficacy and safety of iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide, relative to premix insulin and other insulin options through network meta-analysis. Methods A systematic literatur…